XNASIRON
Market cap1.76bUSD
Jan 10, Last price
59.25USD
1D
-5.27%
1Q
24.07%
Name
IronPlanet Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-76m
L+65.83%
CFO
-73m
L+73.87%
Earnings
Mar 19, 2025
Profile
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||
Revenues | ||||
Cost of revenue | 91,125 | 47,775 | ||
Unusual Expense (Income) | ||||
NOPBT | (91,125) | (47,775) | ||
NOPBT Margin | ||||
Operating Taxes | 99 | (737) | ||
Tax Rate | ||||
NOPAT | (91,224) | (47,038) | ||
Net income | (76,429) 65.83% | (46,090) 12.40% | ||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 199,078 | 53,500 | ||
BB yield | -15.44% | -258.76% | ||
| Debt | ||||
Debt current | 665 | 307 | ||
Long-term debt | 3,537 | 2,361 | ||
Deferred revenue | ||||
Other long-term liabilities | ||||
Net debt | (356,414) | (191,943) | ||
| Cash flow | ||||
Cash from operating activities | (73,462) | (42,252) | ||
CAPEX | (89) | (151) | ||
Cash from investing activities | (89) | (151) | ||
Cash from financing activities | 239,379 | 148,978 | ||
FCF | 84,494 | (223,109) | ||
| Balance | ||||
Cash | 360,382 | 194,611 | ||
Long term investments | 234 | |||
Excess cash | 360,616 | 194,611 | ||
Stockholders' equity | (188,643) | (112,214) | ||
Invested Capital | 535,865 | 290,148 | ||
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | 22,316 | 1,039 | ||
Price | 57.76 190.40% | 19.89 -31.65% | ||
Market cap | 1,288,965 6,134.28% | 20,675 -77.82% | ||
EV | 932,551 | (171,266) | ||
EBITDA | (91,025) | (47,686) | ||
EV/EBITDA | 3.59 | |||
Interest | 737 | |||
Interest/NOPBT | ||||